Journal of Clinical Oncology
Articles in this Issue
Kelim index as predictor of treatment outcome in ovarian cancer surgery.
e17599 Background: The Kelim index, calculated from CA125 kinetics during chemotherapy, is an emerging biomarker for assessing tumor regression and chemo...
Electronic patient reported outcomes in breast cancer patients receiving adjuvant chemotherapy with doxorubicin/cyclophosphamide combined with paclitaxel compared to patients receiving docetaxel/cyclophosphamide.
e12519 Background: Doxorubicin/cyclophosphamide combined with paclitaxel (ACT) and docetaxel/cyclophosphamide (TC) are two of the NCCN preferred regimens...
BMS-986504 in patients (pts) with advanced solid tumors with homozygous <i>MTAP</i> deletion ( <i>MTAP</i> -del): Clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007.
3011 Background: BMS-986504 selectively binds to the PRMT5-MTA complex, which represents a synthetic lethal target in...
Efficacy and safety of nimotuzumab plus AG regimen as conversion therapy for locally advanced pancreatic cancer: A prospective, single-arm study.
e16451 Background: Conversion therapy for locally advanced pancreatic cancer (LAPC) remains a challenging area, with the median overall survival of existi...
A phase I/IIa study to evaluate the tolerability, safety, pharmacokinetics and efficacy of eciruciclib (BPI-1178) alone in advanced solid tumors and in combination with endocrine therapy for advanced or recurrent HR+/HER2- breast cancer.
1064 Background: Eciruciclib (BPI-1178) is a new cyclin-dependent kinases (CDKs) 2/4/6 inhibitor, which has shown strong inhibition on the expression of C...
A TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced cervical cancers with prior anti-PD-(L)1 therapy.
5540 Background: Clinical findings on onatasertib (ATG-008), an oral TORC1/2 inhibitor, showed promising anti-tumor efficacy and manageable safety when us...
Regional disparities in trends of Medicare reimbursements and service volumes for stereotactic radiosurgery among neurosurgeons and radiation oncologists, 2014-2022.
e23051 Background: Stereotactic radiosurgery (SRS) is a minimally invasive alternative to traditional brain surgery for treating intracranial neoplasms. W...
Sexual behavior characteristics in breast cancer patients: NHANES study analysis.
e24071 Background: Breast cancer is the most common malignancy among women, excluding skin cancer, with one in eight women diagnosed in their lifetime in...
Verification of a novel plasma eight-protein signature predicting long-term efficacy of first-line chemoimmunotherapy for advanced non-small cell lung cancer.
e20568 Background: Predicting immuno-chemotherapy (IC) response in advanced non-small cell lung cancer (aNSCLC) remains challenging. We previously develop...
Germline pathogenic variants in cancer predisposition genes and overall survival of women with breast cancer.
10510 Background: The impact of germline pathogenic or likely pathogenic variants (PVs) in cancer predisposition genes on overall survival (OS) after brea...
A global scoping review of barriers and strategies to implementation of geriatric assessment in older adults with cancer.
e13851 Background: There is a lack of practical application of evidence synthesized from the systematic exploration and summarization of barriers and stra...
A phase Ib/II trial of radiotherapy combined with doxorubicin and PD-1 antibody for localized high-risk limbs and trunk soft tissue sarcomas.
11568 Background: Localized high-risk soft tissue sarcomas (STSs) presents a therapeutic challenge due to limited preoperative treatment options. Radiothe...
Clinical utility of pathologist-directed comprehensive comparative molecular profiling for the classification of separate primary lung cancers vs. intrapulmonary metastasis.
8039 Background: Lung cancers can present as multiple pulmonary tumors, representing either separate primary lung carcinomas (SPLCs) or intrapulmonary met...
Machine learning–derived B-cell epitopes classifiers for early detection of renal cell carcinoma.
4554 Background: Renal cell carcinoma (RCC) remains a significant cause of cancer mortality in the United States, with poor outcomes for advanced-stage di...
Phase 1/2, open-label, first-in-human study of the anti-GPC3 T-cell engager SAR444200 in patients with advanced solid tumors: Updated efficacy and biomarker analysis.
2521 Background: SAR444200 is a novel NANOBODY T cell engager that simultaneously binds TCRαβ and glypican-3 (GPC3) to co-engage T cells with GPC3+ tumor...
Personalized recurrence risk stratification in surgically resected non-small cell lung cancer: Multicenter deep learning model development and validation.
e13632 Background: Current adjuvant treatment strategies for surgically resected non-small cell lung cancer (NSCLC) often fail to account for individual p...
Financial toxicity for cancer patients: Out-of-pocket costs by cancer diagnosis in traditional Medicare.
11092 Background: Financial toxicity is defined as the fiscal issues that can arise in a patient’s life related to the costs of medical care (DOI: 10.1093...
Clinical application of a novel, multidisciplinary pharmacovigilance (PV) clinic in patients (pts) with immune-related adverse events (irAEs).
e24091 Background: Multidisciplinary care models can facilitate care of pts with toxicities from cancer therapies. Here, we report the impact of our novel...
Retrospective analysis of overall survival in patients lost to follow-up after incidental neoplasm findings on imaging.
e16486 Background: Early detection and punctual intervention in cancer diagnosis are critical for improving patient outcomes. Despite advancements in canc...
Comparison of dose-dense versus standard neoadjuvant chemotherapy for HER2 negative breast cancer: Retrospective, multicenter, real-world, Japanese study (JONIE5).
e12601 Background: Based on the Norton-Simon model, dose-dense (dd) chemotherapy with shortened intervals between administrations has been adopted in peri...
Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1/2 study (NCT04253145).
8013 Background: Small-cell lung cancer (SCLC) is an aggressive malignancy, accounting for 13% of all lung cancers, with a...
The phase II study of pembrolizumab plus lenvatinib for patients with unresectable cutaneous angiosarcoma (Pembro-Lenva for cAS/PLAS trial).
TPS11586 Background: Cutaneous angiosarcoma (cAS) is a rare cancer that often occurs in elderly people with common recurrence and metastasis after surgery...
Clonal hematopoiesis in patients with non-hematologic cancers: Prevalence and detectability in primary tumor tissue.
e23318 Background: Clonal Hematopoiesis of Indeterminate Potential (CHIP) is defined by leukemia-associated mutations with a variant allele frequency of a...
Identification of targetable <i>EGFR</i> mutations in ovarian cancer.
e17550 Background: Carboplatin and paclitaxel doublet remains the chemotherapy backbone for newly diagnosed ovarian cancer after surgical cytoreduction, a...
Clinical characteristics, treatment, and survival outcomes in small cell ovarian cancer: A population-based analysis and review of the literature.
e17606 Background: Small cell carcinoma of the ovary (SCCO) is a rare and aggressive malignancy with limited epidemiological and prognostic analyses. This...